MC2 Therapeutics Announces Positive Phase 2a Results of Nove

MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data in randomized, double-blinded, placebo-controlled trial in 15 patients:Primary endpoint, HiSCR50

Related Keywords

Berlin , Germany , China , Denmark , Copenhagen , Køavn , Hidradenitis Suppurativa , Lars Iversen , Amber Fennell , Jesperj Lange , European Academy Of Dermatology , Therapeutics Group , Aarhus University Hospital , European Academy , Annual Meeting , Heat Shock Protein , Professor Lars Iversen , Region ,